Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.57 |
| ▸ | DRD1 | P21728 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622047 | 0.94 | CYP3A4 (0.76) | CYP3A4CYP3A5MAOAALDH1A1MEN1 | |
| SCHEMBL5251683 | 0.92 | CYP3A4 (0.73) | CYP3A4CYP3A5MAOAALDH1A1MEN1 | |
| SCHEMBL3619665 | 0.91 | CYP3A4 (0.80) | CYP3A4CYP3A5MAOAALDH1A1MEN1 | |
| SCHEMBL7098287 | 0.89 | MAOA (0.60) | CYP3A4CYP3A5MAOAALDH1A1MEN1 | |
| SCHEMBL3627302 | 0.87 | CYP3A4 (0.64) | CYP3A4CYP3A5MAOAALDH1A1MEN1 | |
| SCHEMBL13845030 | 0.87 | CYP3A4 (0.64) | CYP3A4CYP3A5MAOAALDH1A1MEN1 | |
| SCHEMBL31647216 | 0.83 | LMNA (0.65) | ALDH1A1MEN1KMT2AGAACHRM2 | |
| SCHEMBL4754533 | 0.82 | LMNA (0.62) | MAOAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5302826 | 0.82 | ATM (0.57) | CYP3A4CYP3A5MAOAALDH1A1MEN1 | |
| SCHEMBL8067855 | 0.80 | CHRM2 (0.63) | CYP3A4CYP3A5ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2003-10-30 | — | — | US | claimed |
| EP-0617028-B1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl] piperazine | UCB SA (BE) | 2000-06-14 | — | — | EP | claimed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | claimed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | claimed |
| JP-7002816-A | — | — | None | — | — | JP | disclosed |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | THE GENERAL HOSPITAL CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-9399032-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-5703082-A | ANTIHISTAMINE; TRANQUILIZERS | U C B S.A. (BE) | 1997-12-30 | — | — | US | disclosed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | disclosed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | disclosed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | disclosed |
| JP-H072816-A | ENANTIOMER OF 1-((4-CHLOROPHENYL)PHENYLMETHYLI-4-((4-METHYLPHENYL)SULFONYL)PIPERAZINE AND ITS PREPARATION | UCB SA | 1995-01-06 | — | — | JP | disclosed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | disclosed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | RPLP1, QDPR, RPLP2 | CYP3A4 58/4885CYP3A5 27/4885MAOA 1490/4885 |
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | PINK1, PC, PCK2 | CYP3A4 2752/4885CYP3A5 2835/4885MAOA 1888/4885 |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | PINK1, PC, PCK2 | CYP3A4 2752/4885CYP3A5 2835/4885MAOA 1888/4885 |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | CYP3A4 93/4885CYP3A5 38/4885MAOA 1630/4885 |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | CYP3A4 93/4885CYP3A5 38/4885MAOA 1630/4885 |
| US-20160324850-A1 | Methods and Compositions for Treating Degenerative and Ischemic Disorders | PINK1, PC, PCK2 | CYP3A4 2752/4885CYP3A5 2835/4885MAOA 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.